A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma

Yung Hung Luo, Pei Chun Tseng, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng, Yuh Min Chen

Research output: Contribution to journalReview article

4 Citations (Scopus)


BACKGROUND: The use of liquid tissue, such as circulating cells, to predict treatment response is attracting more attention. OBJECTIVE: The aim of this study was to evaluate association between circulating markers and treatment response. METHODS: One hundred and twelve advanced pulmonary adenocarcinoma patients who were going to receive epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were included. Tumor tissue and plasma specimens were collected before treatment and analyzed for EGFR mutation and plasma IL-6 and IL-8. Pre-treatment peripheral blood CD146+/CD3- cells (as circulating endothelial cells, CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), and CD133+ cells (as cancer stem cells, CSCs) were measured with flow cytometry. RESULTS: The progression-free survival (PFS) was significantly longer in patients with low CEC, low EPC, and low CSC counts than in those with high cell counts (p < 0.001, 0.041, and 0.001, respectively). Multivariate analysis showed that mutant plasma EGFR (pEGFR) was a poor prognostic factor in EGFR-mutated patients (p = 0.048), and there was a tendency for EGFR mutation-negative patients with high IL-6 level to have worse overall survival (p = 0.051). CONCLUSIONS: CECs, EPCs, CSCs, and mutant pEGFR are useful predictive biomarkers of EGFR-TKI treatment efficacy. IL-6 may predict prognosis in advanced lung cancer.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalCancer Biomarkers
Issue number1
Publication statusPublished - Jan 18 2016



  • Adenocarcinoma
  • Cancer stem cells
  • Circulating endothelial cells
  • Cytokines
  • Endothelial progenitor cells
  • Epidermal growth factor receptor (EGFR)

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this